FDA Will Use PET And Biomarkers To Speed Drug Development – Gottlieb
This article was originally published in The Gray Sheet
Executive SummaryFDA's "old-fashioned" regulatory processes have "impeded scientific development" in using assays, biomarkers, genomics and positron emission tomography (PET) to speed drug development, according to FDA Deputy Commissioner for Medical and Scientific Affairs Scott Gottlieb, MD
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.